A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04775485 |
|
Recruitment Status :
Recruiting
First Posted : March 1, 2021
Last Update Posted : December 27, 2023
|
Sponsor:
Day One Biopharmaceuticals, Inc.
Collaborator:
Pacific Pediatric Neuro-Oncology Consortium
Information provided by (Responsible Party):
Day One Biopharmaceuticals, Inc.
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Actual Primary Completion Date : | December 22, 2022 |
| Estimated Study Completion Date : | June 10, 2024 |
| Certification/Extension First Submitted : | December 20, 2023 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
May 9, 2024 |